Imaging of Cognition, Learning, and Memory in Aging
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This investigation is designed to study how the brain functions when it is performing explicit memory tasks, and furthermore how the brain systems supporting performance on these tests change as a function of aging. Implicit memory tasks may be distinguished from explicit memory tests in that explicit memory characterizes the directed or intentional recollection of previously learned information or events. In contrast, implicit (or nonconscious) memory is expressed in the facilitation of performance on some task or judgment on a stimulus owing to a prior presentation of that stimulus, without any necessary conscious awareness of the prior presentation. The investigators propose to use functional Magnetic resonance Imaging (fMRI) to measure brain activity during the performance of carefully designed explicit memory tasks. Comparison of brain activity during the different test conditions will provide information about the brain areas that are involved in mediating specific aspects of performance. Both older and younger individuals will be tested in order to understand age related changes in the brain activity. In order to examine the interactions between participants' differential levels of amyloid burden and their performance on cognitive tasks and fMRI neural activation, the investigators also propose PET imaging of older participants.
| Condition | Intervention |
|---|---|
|
Alzheimer's Disease |
Drug: Florbetaben |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Cross-Sectional |
| Official Title: | Imaging of Cognition, Learning, and Memory in Aging |
| Estimated Enrollment: | 550 |
| Study Start Date: | March 2011 |
| Estimated Study Completion Date: | March 2016 |
| Estimated Primary Completion Date: | March 2016 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
Participants aged 65-85
Participants age 65-85 will receive Florbetan PET tracer to identify presence of amyloid burden.
|
Drug: Florbetaben
Other Name: F-18 BAY
|
| Participants aged 18-30 |
Eligibility| Ages Eligible for Study: | 18 Years to 85 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Probability Sample |
Subjects will be recruited from ads placed in local newspapers and notices posted in the vicinity of Columbia University, the Columbia Presbyterian Medical Center, and in local senior centers that provide written consent for notice placement. We will also utilize a market mailing approach. Letters will be sent to appropriately aged potential subjects randomly selected from commercial lists. Additional elderly subjects will be recruited from the Sergievsky Joint Database. Informed consent will be elicited from all subjects.
Inclusion Criteria:
- Aged 18-30 or 65-85
- Residing in the community of Washington Heights/Inwood/Hamilton Heights
- Must be willing and able to participate
Exclusion Criteria:
- Have a contraindication to PET (e.g, metallic implants, pacemaker, claustrophobia, or cannot lie flat for one hour)
- Pregnancy
- Lactating Women
- Current, past, or anticipated exposure to radiation
- Significant active physical illness
Contacts and Locations| Contact: Daniel J Barulli, M.A. | 212-305-9712 ext 5-9712 | djb2168@columbia.edu |
| Contact: Amanda K Phingbodhipakkiya, B.S. | 212-342-4150 ext 2-4150 | akp2112@columbia.edu |
| United States, New York | |
| Columbia University Medical Center | Recruiting |
| New York, New York, United States, 10032 | |
| Principal Investigator: Yaakov Stern, Ph.D. | |
| Principal Investigator: | Yaakov Stern, PhD | Columbia University |
More Information
No publications provided
| Responsible Party: | Yaakov Stern, Professor of Clinical Neurology, Aging and Dementia, Columbia University |
| ClinicalTrials.gov Identifier: | NCT01297114 History of Changes |
| Other Study ID Numbers: | AAAB0596, R01AG026158 |
| Study First Received: | February 14, 2011 |
| Last Updated: | August 9, 2012 |
| Health Authority: | United States: Food and Drug Administration |
Additional relevant MeSH terms:
|
Alzheimer Disease Dementia Brain Diseases Central Nervous System Diseases Nervous System Diseases |
Tauopathies Neurodegenerative Diseases Delirium, Dementia, Amnestic, Cognitive Disorders Mental Disorders |
ClinicalTrials.gov processed this record on May 23, 2013